Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 274 clinical trials
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

Background In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient s immune system destroys the donor s cells. Or donor immune cells attack the recipient s tissues, called graft-versus-host disease (GVHD). This is less likely when the recipient …

tyrosine
chemotherapy regimen
ejection fraction
hematologic malignancy
acute leukemia
  • 23 views
  • 27 Jan, 2021
  • 2 locations
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers. This research study combines two different ways of fighting disease, antibodies and T …

  • 24 views
  • 01 Mar, 2021
  • 2 locations
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Patients eligible for this study have a type of blood cancer Acute Myeloid Leukemia (AML) which has come back or has not gone away after treatment. The body has different ways of fighting disease and infection, and this research study combines two different ways of fighting cancer with antibodies and …

hematologic malignancy
blast cells
lymphoma
flow cytometry
cancer
  • 10 views
  • 25 Jan, 2021
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

This study is for patients who have lymphoma or leukemia that has come back or has not gone away after treatment. Because there is no standard treatment for this cancer, patients are being asked to volunteer for a gene transfer research study using special immune cells. The body has different …

cyclophosphamide
gilbert's syndrome
lymphoma
anthracycline
cancer
  • 0 views
  • 02 Feb, 2021
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)

This study enrolls patients who have GPC3-positive solid tumors currently. Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called GAP T cells, a new experimental treatment. …

hepatocellular carcinoma
hepatoma
carcinoma
cancer, hepatocellular
tumor cells
  • 6 views
  • 27 Jan, 2021
  • 1 location
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)

This study enrolls patients who have a type of cancer that arises from the liver called hepatocellular carcinoma. The cancer has come back, has not gone away after standard treatment, has spread outside of the liver or the patient cannot receive standard treatment. This research study uses special immune system …

child-pugh-turcotte score
platelet count
liver cancer
neutrophil count
cancer
  • 2 views
  • 28 Jan, 2021
  • 1 location
Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

This is a Phase II prospective trial to assess the rates of donor engraftment using reduced intensity conditioning (RIC) hematopoietic stem cell transplant (HSCT) and post-transplant cyclophosphamide (PTCy) for patients with primary immune deficiencies (PID), immune dysregulatory syndromes (IDS), and inherited bone marrow failure syndromes (IBMFS).

mycophenolate mofetil
stem cell transplantation
granulomatous disease
forced vital capacity
thrombocytopenia absent radii
  • 0 views
  • 24 Jan, 2021
  • 1 location
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.

  • 100 views
  • 24 Jan, 2021
  • 6 locations
Registry of the German CLL Study Group

Long term follow-up of patients with chronic lymphocytic leukemia (CLL), B-prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), Small lymphocytic lymphoma (SLL), T/Natural Killer large granular lymphocyte leukemia (T or NK-LGL), Hairy cell leukemia (HCL) and Richter's transformation

recurrent disease
stem cell transplantation
chronic lymphocytic leukemia
lymphoid leukemia
lymphoma
  • 21 views
  • 11 Feb, 2021
  • 1 location
Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS MU or HF) for AML in Remission

transplantation (HCT) using uniform conditioning regimen including busulfan, fludarabine, and antithymocyte globulin (ATG) in patients with acute myeloid leukemia (AML) in the first complete remission (CR). The

remission
busulfan
ejection fraction
transplant conditioning
graft versus host disease
  • 11 views
  • 22 Jan, 2021
  • 1 location